The biological DMARD baricitinib (Olumiant) has been recommended for listing on the PBS as an alternative option to currently PBS-listed bDMARDs for severe RA. The drug overcame concerns raised about safety when its application was initially evaluated by the PBAC, which deferred its decision pending a TGA review. “The PBAC was of a mind to ...
PBS listings recommended for new bDMARD and two new biosimilars
By Michael Woodhead
23 Apr 2018